Overview: Widal Slide Agglutination Test Panel
Introduction: The Widal Slide Agglutination Test Panel is a diagnostic tool designed for typhoid fever screening using serum samples. In India, typhoid fever (Salmonella Typhi) causes ~1 million cases/year (higher in rural/low-SES with poor sanitation/water), presenting with prolonged fever, abdominal pain, and complications (intestinal perforation). High morbidity from under-testing leading to delayed ceftriaxone/azithromycin, progression to carrier state or mortality. Per microbiology practices aligned with ICMR, National Centre for Disease Control, and IDSP guidelines, the test employs immunoassay for Salmonella Typhi O/H and Paratyphi A/B antigens over 1â€"2 days with high accuracy, valuable for presumptive diagnosis in endemic areas (titre >1:160 or rising significant). This diagnostic falls under infectious disease screening and targets patients with prolonged fever or food/water exposure, addressing accurate detection to guide antibiotics. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling rapid typhoid profiling and reducing transmission. Its serum-based approach ensures reliable agglutination detection.
Other Names: Widal Slide Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry/immunology, compliant with 2025 standards.
Historical Milestone: Widal slide test standard in typhoid endemic areas; in India, widely used despite limitations.
Purpose: The test assesses 4 parameters including Salmonella Typhi O to guide typhoid fever screening, detect antibodies, inform antibiotics.
Test Parameters: 1. Salmonella Typhi O, 2. Salmonella Typhi H, 3. Salmonella Paratyphi A, 4. Salmonella Paratyphi B.
Pretest Condition: No fasting required; patients should have prolonged fever.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on fever duration, water source.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated typhoid including perforation, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: High titre (>1:160) or rising indicates typhoid, necessitating specialist input.
Specialist Consultation: Infectious disease specialists should be consulted for management.
Additional Supporting Tests: Blood culture, Typhidot for confirmation.
Test Limitations: Cross-reactivity/vaccination interference; comprehensive approach required.
References: Indian Journal of Medical Microbiology 2024, Typhoid Studies India 2023.
